HRP20150317T1 - Peptidi trave za cjepivo - Google Patents

Peptidi trave za cjepivo Download PDF

Info

Publication number
HRP20150317T1
HRP20150317T1 HRP20150317TT HRP20150317T HRP20150317T1 HR P20150317 T1 HRP20150317 T1 HR P20150317T1 HR P20150317T T HRP20150317T T HR P20150317TT HR P20150317 T HRP20150317 T HR P20150317T HR P20150317 T1 HRP20150317 T1 HR P20150317T1
Authority
HR
Croatia
Prior art keywords
segment
polypeptide consisting
polypeptide
preparation
grass
Prior art date
Application number
HRP20150317TT
Other languages
English (en)
Inventor
Rod Hafner
Paul Laidler
Guy Layton
Mark Larche
Original Assignee
Circassia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0901927.4A external-priority patent/GB0901927D0/en
Priority claimed from GB0901928A external-priority patent/GB0901928D0/en
Priority claimed from GB0912578A external-priority patent/GB0912578D0/en
Priority claimed from PCT/GB2009/001995 external-priority patent/WO2010018384A1/en
Priority claimed from GB0917871A external-priority patent/GB0917871D0/en
Application filed by Circassia Limited filed Critical Circassia Limited
Publication of HRP20150317T1 publication Critical patent/HRP20150317T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • A61K39/36Allergens from pollen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Claims (15)

1. Pripravak za uporabu u sprječavanju i liječenju alergije na travu, naznačen time, da se pripravak sastoji od: (a) polipeptida koji se sastoji od odsječka KIPAGELQIIDKIDA ili njihove inačice, (b) polipeptida koji se sastoji od odsječka SGKAFGAMAKKGQED ili njihove inačice, i (c) polipeptida koji se sastoji od odsječka LKKAVTAMSEAEK ili njihove inačice, pri čemu je rečena inačinca duži polipeptid sastavljen od najviše 30 aminokiselina u dužini koji sadrži odsječak naveden pod (a), (b) ili (c).
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da sadrži najmanje jednu rečenu inačicu polipeptida u dužini od 20 aminokiselina.
3. Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da sadrži najmanje jednu rečenu inačicu polipeptida u dužini od 17 aminokiselina.
4. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je (a) polipeptid koji se sastoji od odsječka KKIPAGELQIIDKIDA.
5. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da dalje sadrži: (d) polipeptid koji se sastoji od odsječka PEVKYAVFEAALTKAIT ili njihovih inačica, (e) polipeptid koji se sastoji od odsječka FIPMKSSWGA ili njihovih inačica, i (f) polipeptida koji se sastoji od odsječka KSSWGAIWRIDPKKPLK ili njihovih inačica, pri čemu rečena inačica je duži polipeptid od najviše 30 aminokiselina koji sadrži odsječak koji je naveden pod (d), (e) ili (f).
6. Pripravak u skladu s patentnim zahtjevom 5, naznačen time, da je (d) polipeptid koji se sastoji od odsječka KPEVKYAVFEAALTKAIT.
7. Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da sadrži: (a) polipeptid koji se sastoji od odsječka KKIPAGELQIIDKIDA, (b) polipeptid koji se sastoji od odsječka SGKAFGAMAKKGQED, (c) polipeptid koji se sastoji od odsječka LKKAVTAMSEAEK, (d) polipeptid koji se sastoji od odsječka KPEVKYAVFEAALTKAIT, (e) polipeptid koji se sastoji od odsječka FIPMKSSWGA, (f) polipeptid koji se sastoji od odsječka KSSWGAIWRIDPKKPLK, i (g) polipeptid koji se sastoji od odsječka KYDAYVATLTEALR.
8. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je isti otopina u kojoj je koncentracija svakog polipeptida u opsegu od 0.03 do 200 nmol/ml.
9. Pripravak u skladu s patentnim zahtjevom 8, naznačen time, da je koncentracija svakog polipeptida u opsegu od 5 do 200 nmol/ml.
10. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, daje isti farmaceutski pripravak koji sadrži farmaceutski prihvatljiv nosač ili otapalo.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time, da je pripravljen za oralnu primjenu, vanjsku, nazalnu primjenu, potkožnu primjenu, podjezičnu primjenu, intradermalnu primjenu, bukalnu primjenu, epidermalnu primjenu ili u obliku naljepaka ili za primjenu putem inhalacija ili injekcija.
12. Farmaceutski pripravak u skladu s patentnim zahtjevom 10 ili 11, naznačen time, da se koristi u postupku sprječavanja ili liječenja alergije na travu.
13. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 12, naznačen time, da se rečeni postupak koristi za sprječavanje ili liječenje alergije na travu kod ljudi.
14. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 13, naznačen time, da su ljudi oni koji su alergični na travu.
15. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 14, naznačeno time, da su rečeni ljudi: - oni koji su osjetljivi na jednu ili više vrsta alergena polena trave; - oni koji u imaju alergiju na travu zabilježenu u obiteljskoj povijesti; ili - oni koji pokazuju simptome alergije kada su izloženi travi.
HRP20150317TT 2009-02-05 2015-03-19 Peptidi trave za cjepivo HRP20150317T1 (hr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB0901927.4A GB0901927D0 (en) 2009-02-05 2009-02-05 Peptide for IL10 production
GB0901928A GB0901928D0 (en) 2009-02-05 2009-02-05 Peptides for vaccine
GB0912578A GB0912578D0 (en) 2009-07-20 2009-07-20 Peptide for IL-10 production
PCT/GB2009/001995 WO2010018384A1 (en) 2008-08-15 2009-08-14 T-cell antigen peptide from allergen for stimulation of il-10 production
GB0917871A GB0917871D0 (en) 2009-10-12 2009-10-12 Peptides for vaccine
EP10704399.4A EP2393830B8 (en) 2009-02-05 2010-02-05 Grass peptides for vaccine
PCT/GB2010/000198 WO2010089554A1 (en) 2009-02-05 2010-02-05 Peptides for vaccine

Publications (1)

Publication Number Publication Date
HRP20150317T1 true HRP20150317T1 (hr) 2015-04-24

Family

ID=42082585

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150317TT HRP20150317T1 (hr) 2009-02-05 2015-03-19 Peptidi trave za cjepivo

Country Status (23)

Country Link
US (2) US8753644B2 (hr)
EP (2) EP2393830B8 (hr)
JP (2) JP5746053B2 (hr)
KR (1) KR20110111307A (hr)
CN (2) CN102307893B (hr)
AU (1) AU2010212193B2 (hr)
BR (1) BRPI1008802A2 (hr)
CA (1) CA2751500A1 (hr)
DK (1) DK2393830T3 (hr)
EA (1) EA020792B1 (hr)
ES (1) ES2532759T3 (hr)
GB (1) GB2469894B (hr)
HK (1) HK1212358A1 (hr)
HR (1) HRP20150317T1 (hr)
IL (1) IL214257A (hr)
MX (1) MX2011008179A (hr)
NZ (1) NZ594268A (hr)
PL (1) PL2393830T3 (hr)
PT (1) PT2393830E (hr)
SG (1) SG173523A1 (hr)
SI (1) SI2393830T1 (hr)
WO (1) WO2010089554A1 (hr)
ZA (1) ZA201105436B (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307893B (zh) * 2009-02-05 2014-03-26 切尔卡西亚有限公司 用于疫苗的草肽
CA3182519A1 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
AU2014262163A1 (en) 2013-05-03 2015-11-19 Selecta Biosciences, Inc. Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the inducation of immune tolerance
CN107073091A (zh) 2014-09-07 2017-08-18 西莱克塔生物科技公司 用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物
WO2017004561A1 (en) 2015-07-01 2017-01-05 Alk-Abelló A/S Peptide combinations and uses thereof for treating grass allergy
CN110612122A (zh) 2017-03-11 2019-12-24 西莱克塔生物科技公司 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
US11524019B2 (en) 2017-08-21 2022-12-13 Glycom A/S Synthetic composition for reducing allergy symptoms
CN108802216B (zh) * 2018-05-23 2021-04-16 山东出入境检验检疫局检验检疫技术中心 一种使用区域敏感性蛋白组和/或多肽组鉴别刺参产地的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340729C (en) 1988-03-23 1999-09-07 Mohan Bir Singh Ryegrass pollen allergen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1992003550A1 (en) 1990-08-17 1992-03-05 The University Of Melbourne Ryegrass pollen allergen
WO1992016554A1 (en) 1991-03-14 1992-10-01 The University Of Melbourne Protein allergens of the species cynodon dactylon
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
AU651728B2 (en) 1991-08-16 1994-07-28 University Of Melbourne, The Ryegrass pollen allergen
US6441157B1 (en) 1991-11-15 2002-08-27 University Of Melbourne Nucleic acid sequences encoding protein allergens of the species Cynodon dactylon
WO1993010236A1 (en) 1991-11-15 1993-05-27 The University Of Melbourne Protein allergens of the species cynodon dactylon
EP0656012B1 (en) 1992-08-14 2004-11-24 The University Of Melbourne T cell epitopes of ryegrass pollen allergen
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
US6214358B1 (en) 1992-10-30 2001-04-10 Immulogic Pharamaceutical Corp. Protein allergens of the species Cynodon dactylon
AU684501B2 (en) * 1993-03-12 1997-12-18 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
NZ271818A (en) * 1993-08-13 1997-11-24 Immulogic Pharma Corp T cell epitopes of ryegrass pollen antigen
US5820862A (en) 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
GB9412714D0 (en) 1994-06-24 1994-08-17 Lewin Ian V T cill epitopes
WO1996003106A2 (en) 1994-07-26 1996-02-08 University Of Manitoba Allergenic peptides derived from poa pratensis
US7112333B1 (en) 1994-08-05 2006-09-26 Heska Corporation T cell epitopes of ryegrass pollen allergen
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
AT402505B (de) 1995-08-02 1997-06-25 Biomay Prod & Handel Rekombinantes 60 kda pflanzliches panallergen (kofaktor-unabhängige phosphoglyceratmutase; e.c. 5.4.2.1.)
JP2002500198A (ja) 1998-01-09 2002-01-08 サーカシア リミテッド 脱感作のための方法及び組成物
DE19823097A1 (de) * 1998-05-22 1999-11-25 Max Planck Gesellschaft Mittel gegen saisonale Typ-I-Allergien und bakterielle Infektionen
US6989146B2 (en) 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
AUPR775401A0 (en) * 2001-09-18 2001-10-11 Monash University Novel Epitopes and Uses Thereof
AU2002347369A1 (en) 2001-12-05 2003-06-17 Circassia Limited Immunotherapeutic methods and systems
AUPS148202A0 (en) 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
WO2003088997A2 (en) 2002-04-22 2003-10-30 Universiteit Utrecht Holding B.V. Reduction of unwanted immune reactions
GB0210741D0 (en) 2002-05-10 2002-06-19 Medical Res Council Methods of therapy
GB0308988D0 (en) 2003-04-17 2003-05-28 Univ Singapore Molecule
DE102004035337A1 (de) 2004-07-21 2006-03-16 Merck Patent Gmbh Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität
WO2006075253A2 (en) 2005-01-11 2006-07-20 Commissariat A L'energie Atomique Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides.
EP1899367A4 (en) 2005-06-10 2009-06-24 Univ Singapore MUTANT ALLERGENS
DE202005009990U1 (de) * 2005-06-25 2006-11-02 Hengst Gmbh & Co.Kg Vorrichtung zum Abscheiden von Ölteilchen aus dem Kurbelgehäuseentlüftungsgas einer Brennkraftmaschine
US20070092532A1 (en) 2005-10-25 2007-04-26 Board Of Trustees Operating Michigan State University Arthritis vaccines and methods
WO2007063075A1 (en) 2005-11-29 2007-06-07 Actogenix Nv Induction of mucosal tolerance to antigens
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
ES2425486T3 (es) 2007-05-09 2013-10-15 Circassia Limited Análisis de pronóstico para determinar la respuesta de células T a antígenos HLA y uso del mismo en el campo del trasplante de tejidos
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PL2083856T3 (pl) * 2007-08-15 2011-04-29 Circassia Ltd Peptydy do odczulania na alergeny
EP2042193A1 (en) 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
JP5705113B2 (ja) 2008-08-15 2015-04-22 サーカッシア リミテッド Il−10産生の刺激のためのアレルゲン由来のt細胞抗原
CN102307893B (zh) * 2009-02-05 2014-03-26 切尔卡西亚有限公司 用于疫苗的草肽

Also Published As

Publication number Publication date
GB2469894B (en) 2011-09-07
KR20110111307A (ko) 2011-10-10
SG173523A1 (en) 2011-09-29
PL2393830T3 (pl) 2015-07-31
EP2393830A1 (en) 2011-12-14
HK1212358A1 (en) 2016-06-10
MX2011008179A (es) 2011-09-09
EP2393830B1 (en) 2015-01-28
AU2010212193A1 (en) 2011-08-18
GB2469894A (en) 2010-11-03
CN103784952B (zh) 2016-08-17
CA2751500A1 (en) 2010-08-12
GB201001954D0 (en) 2010-03-24
CN102307893B (zh) 2014-03-26
SI2393830T1 (sl) 2015-04-30
EA201171001A1 (ru) 2012-02-28
WO2010089554A8 (en) 2011-10-06
AU2010212193B2 (en) 2015-05-14
JP6215252B2 (ja) 2017-10-18
JP2012516693A (ja) 2012-07-26
WO2010089554A1 (en) 2010-08-12
US20120148612A1 (en) 2012-06-14
PT2393830E (pt) 2015-04-23
BRPI1008802A2 (pt) 2016-03-08
EA020792B1 (ru) 2015-01-30
US8753644B2 (en) 2014-06-17
ES2532759T3 (es) 2015-03-31
EP2891662A1 (en) 2015-07-08
JP2015180646A (ja) 2015-10-15
US20140302071A1 (en) 2014-10-09
CN103784952A (zh) 2014-05-14
ZA201105436B (en) 2012-09-26
JP5746053B2 (ja) 2015-07-08
CN102307893A (zh) 2012-01-04
NZ594268A (en) 2013-05-31
DK2393830T3 (en) 2015-04-27
EP2393830B8 (en) 2015-03-18
IL214257A (en) 2016-06-30
IL214257A0 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
HRP20150317T1 (hr) Peptidi trave za cjepivo
HRP20171909T1 (hr) Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe
RU2020111236A (ru) Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
JP2015517488A5 (hr)
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
PE20240686A1 (es) Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
JP2011241213A5 (hr)
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
HRP20220717T1 (hr) Modificirani pripravci mrna
JP2015518818A5 (hr)
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
AR093481A1 (es) Parche de varios dias para la administracion transdermica de rotigotina
BR112014008036A2 (pt) tratamento de rinite
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
CA2817787C (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
RU2018120387A (ru) Ангиотензин в лечении состояний головного мозга
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
BR112015000183A2 (pt) proteínas de superfície específicas de variante (vsp) de protozoário como carreadores para entrega de fármaco oral
HRP20160481T1 (hr) Peptidi za cjepiva protiv alergije na brezu
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
RU2016114098A (ru) Новое производное аналога инсулина
HRP20170794T1 (hr) Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a
BRPI1008103A2 (pt) " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos "
WO2005090387A3 (en) Histone h2a peptide derivatives and analogs and methods of use thereof